Title | Actinium’s iomab complete analysis. |
URL | https://mellalta.com/actiniums-multi-billion-dollar-market-for-targeted-conditioning-with-their-revolutionary-antibody-warhead-enabling-awe-platform/ |
Category | Fitness Health --> Conditions and Diseases |
Meta Keywords | Actinium pharmaceutical, iomab-B, Sierra tirals, AWE platform, Actinium’s AWE platform, ATNM, ATNM stalks, ATNM trials, SIERRA trials, Actinium’s CD45, BMT, AML, Bone marrow transplant (BMT), Actinium’s iomab-B |
Meta Description | Actinium Pharmaceuticals is a clinical stage biopharmaceutical company, with an impressive Antibody Warhead Enabling (AWE) technology. The technology enables the development of breakthrough Antibody Radiation-Conjugates (ARCs) |
Owner | Emma Stones |
Description |
Actinium’s clinical program which are still ongoing have already shown some high efficacy and what we, Mellalta Meets could say, that the promising new platform of AWE based target conditioning therapies and their unique combination approach is going to be something to keep an eye for, as the company looks for BLA submission for its lead product by 2021-2022 |